PMC:7381711 / 8329-8573 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T60","span":{"begin":15,"end":22},"obj":"Body_part"}],"attributes":[{"id":"A60","pred":"fma_id","subj":"T60","obj":"http://purl.org/sig/ont/fma/fma82839"}],"text":"The utility of heparin as an anticoagulant in COVID-19 was first posited by a retrospective report of 449 patients with COVID-19 from Wuhan, China, where prophylaxis in medical patients is relatively uncommon due to a low incidence of VTE (48)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"312","span":{"begin":106,"end":114},"obj":"Species"},{"id":"313","span":{"begin":177,"end":185},"obj":"Species"},{"id":"318","span":{"begin":15,"end":22},"obj":"Chemical"},{"id":"326","span":{"begin":46,"end":54},"obj":"Disease"},{"id":"327","span":{"begin":120,"end":128},"obj":"Disease"},{"id":"328","span":{"begin":235,"end":238},"obj":"Disease"}],"attributes":[{"id":"A312","pred":"tao:has_database_id","subj":"312","obj":"Tax:9606"},{"id":"A313","pred":"tao:has_database_id","subj":"313","obj":"Tax:9606"},{"id":"A318","pred":"tao:has_database_id","subj":"318","obj":"MESH:D006493"},{"id":"A326","pred":"tao:has_database_id","subj":"326","obj":"MESH:C000657245"},{"id":"A327","pred":"tao:has_database_id","subj":"327","obj":"MESH:C000657245"},{"id":"A328","pred":"tao:has_database_id","subj":"328","obj":"MESH:D054556"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The utility of heparin as an anticoagulant in COVID-19 was first posited by a retrospective report of 449 patients with COVID-19 from Wuhan, China, where prophylaxis in medical patients is relatively uncommon due to a low incidence of VTE (48)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T81","span":{"begin":46,"end":54},"obj":"Disease"},{"id":"T82","span":{"begin":120,"end":128},"obj":"Disease"},{"id":"T83","span":{"begin":235,"end":238},"obj":"Disease"}],"attributes":[{"id":"A81","pred":"mondo_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A82","pred":"mondo_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A83","pred":"mondo_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/MONDO_0005399"}],"text":"The utility of heparin as an anticoagulant in COVID-19 was first posited by a retrospective report of 449 patients with COVID-19 from Wuhan, China, where prophylaxis in medical patients is relatively uncommon due to a low incidence of VTE (48)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T39","span":{"begin":76,"end":77},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T40","span":{"begin":216,"end":217},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T41","span":{"begin":240,"end":242},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"}],"text":"The utility of heparin as an anticoagulant in COVID-19 was first posited by a retrospective report of 449 patients with COVID-19 from Wuhan, China, where prophylaxis in medical patients is relatively uncommon due to a low incidence of VTE (48)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T97","span":{"begin":15,"end":22},"obj":"Chemical"},{"id":"T98","span":{"begin":29,"end":42},"obj":"Chemical"}],"attributes":[{"id":"A97","pred":"chebi_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/CHEBI_28304"},{"id":"A98","pred":"chebi_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/CHEBI_50249"}],"text":"The utility of heparin as an anticoagulant in COVID-19 was first posited by a retrospective report of 449 patients with COVID-19 from Wuhan, China, where prophylaxis in medical patients is relatively uncommon due to a low incidence of VTE (48)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T58","span":{"begin":0,"end":244},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The utility of heparin as an anticoagulant in COVID-19 was first posited by a retrospective report of 449 patients with COVID-19 from Wuhan, China, where prophylaxis in medical patients is relatively uncommon due to a low incidence of VTE (48)."}

{"project":"2_test","denotations":[{"id":"32519894-30300652-2138175","span":{"begin":240,"end":242},"obj":"30300652"}],"text":"The utility of heparin as an anticoagulant in COVID-19 was first posited by a retrospective report of 449 patients with COVID-19 from Wuhan, China, where prophylaxis in medical patients is relatively uncommon due to a low incidence of VTE (48)."}